Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) FCF Margin: 2016-2025

Historic FCF Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 10,648.20%.

  • Rocket Pharmaceuticals' FCF Margin fell 75116.00% to 10,648.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 10,723.69%, marking a year-over-year decrease of 2092.00%. This contributed to the annual value of 11,430.86% for FY2024, which is 15875.00% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its FCF Margin stood at 10,648.20% for Q3 2025, which was up 2.76% from 10,362.37% recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' FCF Margin registered a high of 15,925.10% during Q2 2021, and its lowest value of 1,423.42% during Q1 2021.
  • For the 3-year period, Rocket Pharmaceuticals' FCF Margin averaged around 11,248.98%, with its median value being 11,749.57% (2023).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' FCF Margin spiked by 1,458,462bps in 2021, and later crashed by 690,660bps in 2022.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' FCF Margin stood at 7,107.13% in 2021, then skyrocketed by 553,184bps to 12,638.97% in 2022, then plummeted by 540,791bps to 7,231.06% in 2023, then spiked by 275,858bps to 9,989.64% in 2024, then slumped by 75,116bps to 10,648.20% in 2025.
  • Its last three reported values are 10,648.20% in Q3 2025, 10,362.37% for Q2 2025, and 11,897.03% during Q1 2025.